Shares in ThromboGenics NV reached an all-time during early trading Tuesday on news that its lead drug candidate, microplasmin, reached the primary endpoint in the first of two Phase III trials in the treatment of symptomatic focal vitreomacular adhesion (VMA). (BioWorld International)

LONDON — Bolstered by two fundraisings, Vernalis plc is on the hunt for a merger or acquisition that will bring an advanced and unpartnered clinical program into its pipeline. The company also is interested in in-licensing earlier-stage programs. (BioWorld International)